Mifepristone at home

Cameron, Sharon; Reynolds-Wright, John Joseph

doi:10.1136/bmj.o819

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mifepristone not only has anti-progestin effects but also affects the hypothalamic-pituitary-ovarian axis. It can act on the hypothalamus to inhibit the secretion of gonadotropin-releasing hormone, affecting FSH and LH secretion, and it can also directly act on the pituitary gland to inhibit FSH and LH release, further lowering serum FSH and LH levels, inducing amenorrhea [17] . Mifepristone's indications have not yet been included in HMB, but studies in AUB caused by AUB-L and AUB-A have observed that low-dose (2.5-10mg) Mifepristone can achieve amenorrhea rates of 41-98.9% [18][19][20][21][22][23][24] , and high-dose (50mg) Mifepristone can achieve a 100% amenorrhea rate [25] .…”

Section: Discussionmentioning

confidence: 99%

Effects of Management of Heavy Menstrual Bleeding of Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation

Yang,

Han,

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective Heavy menstrual bleeding (HMB) was an underestimated bleeding complications of hematopoietic stem cell transplantation (HSCT). The study aims to investigate the benefits of menstrual management in women undergoing HSCT.Methods Patients who had undergone HSCT in the Gynecological Endocrinology Clinic of Peking University People's Hospital were included in ten years. The data of hematology and menstruation of all participants had been collected. The management methods of intervention group include GnRHa, COC or low-dose mifepristone. Patients who did not receive management were included in the control group.Results There were 112 patients included in the intervention group and 218 patients included in the control group. There were 90.0% of patients presenting with HMB before HSCT. In the control group, 83.5% of patients experienced uterine bleeding in the LAFR, while only 22.3% did in the intervention group. The rate of recurrent uterine bleeding after HSCT was significantly higher in the control group (50.9% vs. 17.9%, P < 0.001). Patients who did not undergo menstrual management had a higher risk of uterine bleeding than those who did (OR = 18.12, P < 0.001).Conclusion Menstrual management significantly reduces the incidence of uterine bleeding in HSCT patients and acts as a protective factor against uterine bleeding in the LAFR.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Management of Heavy Menstrual Bleeding of Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation

Yang,

Han,

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Effects of management of heavy menstrual bleeding of patients undergoing haploidentical hematopoietic stem cell transplantation

Han,

Zhang,

Jiang

et al. 2024

Intl J Gynecology & Obste

View full text Add to dashboard Cite

ObjectiveTo investigate the benefits of menstrual management in women undergoing hematopoietic stem cell transplantation (HSCT), in whom heavy menstrual bleeding (HMB) can be an underestimated bleeding complication.MethodsThis was a retrospective cohort study. Patients who had undergone HSCT in the Gynecological Endocrinology Clinic of Peking University People's Hospital were included over 10 years. The data of hematology and menstruation for all participants were collected. The management methods of the intervention group include gonadotropin‐releasing hormone agonists (GnRHa), combined oral contraceptives (COC), or low‐dose mifepristone. Patients who did not receive management were included in the control group.ResultsThere were 112 patients included in the intervention group and 218 patients included in the control group. In all, 90.0%(297/330) of patients presented with HMB before HSCT. In the control group, 83.5%(182/218) of patients experienced menstruation in the laminar air‐flow room (LAFR), whereas only 22.3%(25/112) did in the intervention group. After leaving the LAFR, the incidence of recurrent uterine bleeding was significantly reduced in the intervention group (17.9%(20/112/) versus 50.9%(111/218), p < 0.001). Patients who did not undergo menstrual management had a higher risk of bleeding than those who did (odds ratio 18.12, p < 0.001).ConclusionMenstrual management significantly reduces the incidence of HMB in HSCT patients and acts as a protective factor to prevent menstrual bleeding in the LAFR.

show abstract

Mifepristone at home

Cited by 2 publications

References 7 publications

Effects of Management of Heavy Menstrual Bleeding of Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation

Effects of Management of Heavy Menstrual Bleeding of Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation

Effects of management of heavy menstrual bleeding of patients undergoing haploidentical hematopoietic stem cell transplantation

Contact Info

Product

Resources

About